Solid Dosage
GEA designs, produces and delivers innovative, integrated solutions for every stage of the manufacturing process of anti-diabetic drugs
With diabetes and the global anti-diabetes drug market on the rise, demand for GEA technologies for the production of these life-saving drugs is already high and set to increase, particularly in new markets and emerging economies
It is estimated that approximately 6.4% of the adult population worldwide has diabetes, leading to a huge demand for oral anti-diabetes drugs. To be able to cater for this demand, high-volume or mass production of these medicines is a fundamental requirement. It enables companies to produce goods faster and reduce the overall per unit production cost, allowing them to make anti-diabetes medications available to less-developed countries.
GEA has been instrumental in designing, producing and delivering innovative, integrated solutions for every stage of the manufacturing process: from materials handling to tablet coating, automation and monitoring. We continue to support this high-volume batch-based production with ongoing improvements and innovative developments.
One example is our range of double-sided tablet presses to accommodate the fact that many oral anti-diabetes medicines are bilayer combination drugs, consisting of two separate layers for each API.
Another trend that we have observed is the move towards continuous manufacturing (CM). Providing increased yields, lower utility consumption and reduced waste, CM meets the industry’s demands for improved production economics and increased manufacturing flexibility.
Focusing on quality during the whole product lifecycle and decreasing any associated risks, GEA is helping its customers to develop, evaluate and optimize continuous processing techniques to enable them to bring new products to market faster and cheaper.
Showing 4 of 26

Combining process monitoring using online analyzers, together with solid process engineering principles and advanced process modelling techniques will enable processes to be actively controlled in order to compensate for input variations.

Innovative CIP concepts of GEA meet comprehensive high standards. Our experts guarantee product safety at every point of the process. Every upgrade is adapted to individual local conditions and customer requirements and leads to noticeable savings.

Contained Materials Handling solutions for Primary and Secondary Pharmaceuticals and Healthcare. With extensive experience within the generics sector, supply a wide range of technologies and equipment that improve and enhance the efficiency and performance of Oral Solid Dosage production.

The ConsiGma® DC for direct compression is the latest expansion of GEA's continuous portfolio for cost effective, compact, high yield manufacturing systems. It offers a robust and flexible manufacturing method for a wide range of products.
Automated milking has become the first choice for many modern dairy farms. The benefits are compelling, and with a new batch milking solution from GEA, automated group milking for large dairy herds is possible without the need – and expense – of rebuilding existing facilities.
GEA has once again earned the highest rating – Platinum – in the globally recognized EcoVadis sustainability assessment. With a score of 92 out of 100, the machinery and plant manufacturer has improved significantly from last year’s result of 82 points. For the second year in a row, GEA ranks among the top one percent of more than 150,000 rated companies across 185 countries.
At Carlsberg’s Fredericia brewery, GEA VARIVENT valves are part of a long-game strategy. By reusing core valve bodies, retrofitting actuators and control tops, and planning maintenance around brewing seasons, Carlsberg extends asset life, reduces downtime and supports its ambitious water and sustainability targets.